European Journal of Biomedical and Pharmaceutical Sciences

A COMPARATIVE STUDY ON THE MEDICATION ADHERENCE AND ADVERSE EFFECTS OF STANDARD TRIPLE THERAPY AND CONCOMITANT THERAPY FOR HELICOBACTER PYLORI ERADICATION

Remya S. Valooran*, Jayakrishnan S. S. and Krishnandas Devadas

ABSTRACT

Helicobacter pylori is a gram-negative bacterium found on the luminal surface of the gastric epithelium that induces chronic inflammation of the underlying mucosa. The first-line choice of treatment for H. pylori infection was standard triple therapy for 7-14 days. Over the past few years, the efficacy of standard triple therapy has decreased, with eradication rates of <80%. Instead of conventional triple therapy, concomitant therapy can be used. The objective of the study was to compare medication adherence and adverse effects of standard triple therapy for 14 days and concomitant therapy for 10 days and to estimate the symptomatic relief in patients receiving these therapies. Patients who have satisfied the inclusion and exclusion criteria were enrolled for the study. Patients were divided into two groups, one group receiving the concomitant therapy and other under Standard triple therapy. Patient demographic details, medication adherence details, adverse effects and symptom severities were collected in a data collection proforma. There was no significant difference between the two groups regarding their medication adherence (p=0.942) and ADR. There was a significant improvement in the symptoms after completion of treatment (p<0.01) for both groups. This study was able to find the adherence and adverse effects of standard triple therapy and concomitant therapy for H. pylori eradication. Majority of patients shown good adherence to therapy but a number of patients were not getting maximum benefit due to the non adherence.

Keywords: Adverse effects, Concomitant therapy, Helicobacter Pylori, Medication Adherence, Standard triple therapy.